Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

被引：42

作者：

Robert, C. ^{[1
]}

Karaszewska, B. ^{[2
]}

Schachter, J. ^{[3
]}

Rutkowski, P. ^{[4
,5
]}

Mackiewicz, A. ^{[6
]}

Stroyakovskiy, D. ^{[7
]}

Lichinitser, M. ^{[8
]}

Dummer, R. ^{[9
]}

Grange, F. ^{[10
]}

Mortier, L. ^{[11
]}

Chiarion-Sileni, V. ^{[12
]}

Drucis, K. ^{[13
]}

Krajsova, I. ^{[14
]}

Hauschild, A. ^{[15
]}

Mookerjee, B. ^{[16
]}

Legos, J. ^{[16
]}

Schadendorf, D. ^{[17
]}

机构：

[1] Gustave Roussy, CH-8091 Villejuif Paris, France

[2] Przychodnia Lekarska Komed, Konin, Poland

[3] Chaim Sheba Med Ctr, Ramat Gan, Israel

[4] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[5] Inst Oncol, Warsaw, Poland

[6] Poznan Univ Med Sci, Poznan, Poland

[7] Moscow City Oncol Hosp 62, Moscow, Russia

[8] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[9] Univ Zurich Hosp, Zurich, Switzerland

[10] Ctr Hosp Univ Robert Debre, Reims, France

[11] Univ Lille 2, CHRU Lille, Lille, France

[12] Veneto Oncol Inst, Padua, Italy

[13] Med Univ, Swissmed Ctr Zdrowia SA, Gdansk, Poland

[14] VFN 1LF UK Praha, Prague, Czech Republic

[15] Univ Hosp Schleswig Holstein, Kiel, Germany

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Univ Hosp Essen, Essen, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31820-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3301

引用

页码：S663 / S664

页数：3

共 35 条

[1] Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
Long, Georgina V.
Stroyakovskiy, Daniil
Gogas, Helen
Levchenko, Evgeny
De Braud, Filippo G.
Larkin, James M. G.
Garbe, Claus
Jouary, Thomas
Hauschild, Axel
Grob, Jean Jacques
Chiarion-Sileni, Vanna
Lebbe, Celeste
Mandala, Mario
Millward, Michael
DeMarini, Douglas James
Irani, Jhangir G.
Jin, Fan
Swann, R. Suzanne
Mookerjee, Bijoyesh
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) plus trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma
Robert, C.
Karaszewska, B.
Schachter, J.
Rutkowski, P.
Mackiewicz, A.
Stroyakovskiy, D.
Dummer, R.
Grange, F.
Mortier, L.
Chiarion-Sileni, V.
Drucis, K.
Krajsovÿ, I.
Hauschild, A.
Mookerjee, B.
Legos, J. J.
Zhang, Y.
Lane, S.
Schadendorf, D.
ANNALS OF ONCOLOGY, 2016, 27
[3] COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma
Long, Georgina V.
Stroyakovsky, Daniil L.
Gogas, Helen
Levchenko, Eugeny
de Braud, Filippo
Larkin, James M. G.
Garbe, Claus
Jouary, Thomas
Hauschild, Axel
Grob, Jean Jacques
Chiarion-Sileni, Vanna
Lebbe, Celeste
Mandala, Mario
Millward, Michael
DeMarini, Douglas James
Irani, Jhangir G.
Le, Ngocdiep
Casey, Michelle
Patel, Kiran
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Grob, Jean Jacques
Amonkar, Mayur M.
Karaszewska, Boguslawa
Schachter, Jacob
Dummer, Reinhard
Mackiewicz, Andrzej
Stroyakovskiy, Daniil
Drucis, Kamil
Grange, Florent
Chiarion-Sileni, Vanna
Rutkowski, Piotr
Lichinitser, Mikhail
Levchenko, Evgeny
Wolter, Pascal
Hauschild, Axel
Long, Georgina V.
Nathan, Paul
Ribas, Antoni
Flaherty, Keith
Sun, Peng
Legos, Jeffrey J.
McDowell, Diane Opatt
Mookerjee, Bijoyesh
Schadendorf, Dirk
Robert, Caroline
LANCET ONCOLOGY, 2015, 16 (13): : 1389 - 1398
[5] Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma
Wang, T. W.
Smith, J. L.
Carlino, M.
Burmeister, B.
Pinkham, M. B.
Fogarty, G. B.
Christie, D.
Estall, V.
Shackleton, M.
Wolfe, R.
Phuong, T. L. T.
Paton, E. J.
Steel, V.
Williams, N. C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S133 - S134
[6] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
Grippo, J. F.
Zhang, W.
Heinzmann, D.
Yang, K. H.
Wong, J.
Joe, A. K.
Munster, P.
Sarapa, N.
Daud, A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 103 - 111
[7] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
Gao, Tianfu
Liu, Jia
Wu, Jing
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
[8] Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
Wang, Wei
Smith, Jessica Louise
Carlino, Matteo Salvatore
Burmeister, Bryan
Pinkham, Mark Blayne
Fogarty, Gerald Blaise
Christie, David Robert Harry
Estall, Vanessa
Shackleton, Mark
Clements, Arthur
Wolfe, Rory
Le Thi Phuong Thao
Paton, Elizabeth Jane
Steel, Victoria
Williams, Narelle Catherine
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 30 : 95 - 99
[9] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
Igor Puzanov
Journal of Translational Medicine, 13 (Suppl 1)
[10] Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant unresectable or metastatic melanoma (MM).
Long, Georgina V.
Eroglu, Zeynep
Infante, Jeffrey R.
Patel, Sapna Pradyuman
Daud, Adil
Johnson, Douglas Buckner
Gonzalez, Rene
Kefford, Richard
Hamid, Omid
Schuchter, Lynn Mara
Cebon, Jonathan S.
Sharfman, William Howard
McWilliams, Robert R.
Sznol, Mario
Weber, Jeffrey S.
Mookerjee, Bijoyesh
Gasal, Eduard
Redhu, Suman
Flaherty, Keith T.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 →